Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study

PurposeThe need for adjuvant therapy (AT) following neoadjuvant chemoimmunotherapy (nICT) and surgery in esophageal squamous cell cancer (ESCC) remains uncertain. This study aims to investigate whether AT offers additional benefits in terms of recurrence-free survival (RFS) for ESCC patients after n...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Frontiers in Immunology
المؤلفون الرئيسيون:	Shu-Han Xie, Li-Tao Yang, Hai Zhang, Zi-Lu Tang, Zhi-Wei Lin, Yi Chen, Zhi-Nuan Hong, Rong-Yu Xu, Wan-Li Lin, Ming-Qiang Kang
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2024-02-01
الموضوعات:	adjuvant therapy neoadjuvant chemoimmunotherapy esophageal cancer propensity score matching recurrence-free survival
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1332492/full